Intervirology 2001;44:215–218
(DOI:10.1159/000050049)

Hepatitis C Virus and GBV-C/Hepatitis G Virus in Argentine Patients with Porphyria Cutanea Tarda

Oubiña J.R.a · Quarleri J.F.a · Sawicki M.A.b · Mathet V.L.a · Ruiz V.a · Schroder T.b · Méndez M.c · Parera V.c · Muramatsu H.c · Battle A.c · González Cappa S.M.a · Fainboim H.A.b
aDepartment of Microbiology, Faculty of Medicine, University of Buenos Aires, bCIPYP Buenos Aires, and cHepatology Unit, Muñiz Hospital, Buenos Aires, Argentina
email Corresponding Author


 goto top of outline Key Words

  • GBV-C/HGV
  • Hepatitis C virus
  • Porphyria cutanea tarda

 goto top of outline Abstract

To investigate hepatitis C virus (HCV) and GBV-C/hepatitis G virus (HGV) genotype prevalence among HCV-infected porphyria cutanea tarda (PCT) patients, 19 HCV-infected patients with associated PCT were studied. A control group of 53 age-matched HCV-infected patients without associated PCT was selected. Eighteen of the 19 serologically positive HCV-PCT patients showed HCV RNA in serum. Genotype 1b was the most prevalent among both HCV-PCT patients (72.2%; 13/18) and age-matched HCV controls (50.9%; 27/53). Such different genotypic prevalence failed to reach statistical significance (=χ2 with Yates’ correction, p = 0.19). The single HCV-PCT patient without detectable HCV RNA was also infected with genogroup 3 GBV-C/HGV. This GBV-C/HGV RNA prevalence (5.3%) among HCV-PCT patients is not statistically different from that observed among Argentine blood donors (5.5%; 11/200). To our knowledge, these results show for the first time the molecular epidemiology of both HCV and GBV-C/HGV associated to PCT in America.

Copyright © 2001 S. Karger AG, Basel


 goto top of outline References
  1. Lamoril J, Andant C, Bogard C, Puy H, Gouya L, Pawlotsky J-M, Da Silva V, Soulé J-C, Deybach J-C, Nordmann Y: Epidermiology of hepatitis C and G in sporadic and familial porphyria cutanea tarda. Hepatology 1998;27:848–852.
  2. Chuang TY, Brashear R, Lewis C: Porphyria cutanea tarda and hepatitis C virus: A case-control study and meta-analysis of the literature. J Am Acad Dermatol 1999;41:31–36.
  3. Kiyosawa K, Tanaka E: GB virus C/hepatitis G virus. Intervirology 1999;42:185–195.
  4. Mancini C, Griso D, Rivanera D, Macri A, Casino C, Lilli D: Porphyria cutanea tarda and hepatitis G and C virus infection. Eur J Clin Microbiol Infect Dis 1998;17:534–535.
  5. Oubiña JR, Quarleri JF, Rudzinski M, Parks C, Badía I, González Cappa SM: Genomic characterization of hepatitis C virus isolates from Argentina. J Med Virol 1995;47:97–104.

    External Resources

  6. Quarleri JF, Robertson BH, Mathet V, Feld M, Espínola L, Requeijo MP, Mandó O, Carballal G, Oubiña JR: Genomic and phylogenetic analysis of hepatitis C virus isolates from Argentine patients: a six-year retrospective study. J Clin Microbiol 2000;38:4560–4568.

    External Resources

  7. Quarleri JF, Mathet VL, Feld M, Ferrario D, Della Latta MP, Verdun R, Sánchez DO, Oubiña JR: GBV-C/HGV groups and subgroups: Classification by an RFLP method based on the phylogenetic analysis of the 5′untranslated region. J Clin Microbiol 1999;37:1340–1347.

    External Resources

  8. Rivanera D, Lilli D, Griso D, Macri A, Mancini C: Hepatitis C in patients with porphyria cutanea tarda: Relationship to HCV genotypes. New Microbiol 1998;21:329–334.
  9. Maertens G, Stuyver L: Genotypes and genetic variation of hepatitis C virus; in Harrison T, Zuckerman A (eds): The Molecular Medicine of Viral Hepatitis. Chichester, Wiley, 1997, pp 183–233.
  10. Bonkovsky HL, Poh-Fitzpatrick M, Pimstone N, Obando J, Di Bisceglie A, Tattrie C, Tortorelli K, LeClair P, Mercurio MG, Lambrecht RW: Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology 1998;27:1661–1669.
  11. Semprini AE, Persico T, Thiers V, Oneta M, Tuveri R, Serafini P, Boschini A, Giuntelli S, Pardi G, Brechot C: Absence of hepatitis C virus and detection of hepatitis G virus/GB virus C RNA sequences in the semen of infected men. J Infect Dis 1998;177:848–854.
  12. Oubiña JR, Mathet V, Feld M, Della Latta MP, Ferrario D, Verdún R, Libonatti O, Fernández J, Carballal G, Sánchez DO, Quarleri JF: Genetic diversity of GBV-C/HGV strains among HIV infected-IVDU and blood donors from Buenos Aires, Argentina. Virus Res 1999;65:121–129.

    External Resources


 goto top of outline Author Contacts

José Raúl Oubiña
Department of Microbiology, Faculty of Medicine, University of Buenos Aires
Paraguay 2155. Piso 11
1121 Buenos Aires (Argentina)
Tel. +54 11 4508 3689, Fax +54 11 4508 3705, E-Mail joubina@fmed.uba.ar


 goto top of outline Article Information

Received: Received: March 14, 2000
Accepted after revision: November 27, 2000
Number of Print Pages : 4
Number of Figures : 0, Number of Tables : 1, Number of References : 12


 goto top of outline Publication Details

Intervirology (International Journal of Basic and Medical Virology)
Founded 1973 by J.L. Melnick; continued by F. Rapp (1986–1990); M.J. Buchmeier and C.R. Howard (1991–1993)

Vol. 44, No. 4, Year 2001 (Cover Date: July-August 2001)

Journal Editor: Rüdiger W. Braun, Stuttgart
ISSN: 0300–5526 (print), 1423–0100 (Online)

For additional information: http://www.karger.com/journals/int


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.